GlaxoSmithKline's ViiV Healthcare Wins First FDA OK for Two-Drug HIV Regimen Post author:Sam Post published:November 21, 2017 Post category:BioPharma HIV patients have a new maintenance drug in their arsenal of medication. Source: BioSpace You Might Also Like 5 Smaller Biotechs That are Flying Under-the-Radar December 6, 2017 TCR2 Therapeutics Snags $125 Million To Expand T-Cell Program March 20, 2018 Catalyst Biosciences To Present At 19th Annual BIO CEO & Investor Conference February 2, 2017
